loading
前日終値:
$18.37
開ける:
$18.51
24時間の取引高:
1.95M
Relative Volume:
1.62
時価総額:
$1.69B
収益:
$203.45M
当期純損益:
$-351.45M
株価収益率:
-4.2769
EPS:
-4.55
ネットキャッシュフロー:
$-369.41M
1週間 パフォーマンス:
+14.00%
1か月 パフォーマンス:
+13.27%
6か月 パフォーマンス:
+98.57%
1年 パフォーマンス:
+122.65%
1日の値動き範囲:
Value
$18.51
$19.76
1週間の範囲:
Value
$17.32
$19.76
52週間の値動き範囲:
Value
$5.12
$20.33

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
名前
Travere Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
888-969-7879
Name
住所
3611 VALLEY CENTRE DR, SAN DIEGO
Name
職員
380
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
TVTX's Discussions on Twitter

TVTX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TVTX
Travere Therapeutics Inc
19.46 1.69B 203.45M -351.45M -369.41M -4.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-10 開始されました Cantor Fitzgerald Overweight
2024-10-21 アップグレード Wells Fargo Equal Weight → Overweight
2024-10-16 開始されました Scotiabank Sector Outperform
2024-09-09 アップグレード Guggenheim Neutral → Buy
2024-03-27 ダウングレード Guggenheim Buy → Neutral
2023-12-05 アップグレード Citigroup Neutral → Buy
2023-11-20 開始されました Citigroup Neutral
2023-09-22 ダウングレード Wells Fargo Overweight → Equal Weight
2023-09-21 ダウングレード William Blair Outperform → Mkt Perform
2023-09-06 再開されました Evercore ISI Outperform
2023-07-21 開始されました JP Morgan Overweight
2023-06-07 再開されました Piper Sandler Neutral
2023-05-22 開始されました TD Cowen Outperform
2023-05-05 アップグレード Bryan Garnier Sell → Neutral
2023-03-01 開始されました Guggenheim Buy
2023-02-21 アップグレード Wedbush Neutral → Outperform
2022-12-14 開始されました Stifel Hold
2022-12-05 開始されました Wells Fargo Overweight
2022-09-21 開始されました Bryan Garnier Sell
2022-07-14 再開されました Canaccord Genuity Buy
2022-03-31 開始されました Piper Sandler Overweight
2022-02-28 開始されました H.C. Wainwright Buy
2021-05-26 ダウングレード Wedbush Outperform → Neutral
すべてを表示

Travere Therapeutics Inc (TVTX) 最新ニュース

pulisher
02:00 AM

What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings? - Defense World

02:00 AM
pulisher
Jan 21, 2025

Leerink Partnrs Issues Optimistic Estimate for TVTX Earnings - MarketBeat

Jan 21, 2025
pulisher
Jan 19, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World

Jan 19, 2025
pulisher
Jan 18, 2025

Research Analysts Issue Forecasts for TVTX FY2024 Earnings - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

HC Wainwright Issues Pessimistic Forecast for TVTX Earnings - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

What is HC Wainwright’s Estimate for TVTX FY2029 Earnings? - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

FY2029 Earnings Forecast for TVTX Issued By HC Wainwright - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail

Jan 15, 2025
pulisher
Jan 15, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 at HC Wainwright - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart

Jan 14, 2025
pulisher
Jan 14, 2025

Alport Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail

Jan 14, 2025
pulisher
Jan 14, 2025

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2%Here's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Travere Therapeutics Provides Corporate Update and 2025 Outlook - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Travere's FILSPARI Drives $50M Q4 Sales, European Expansion Gains Momentum with Multi-Country Launch - StockTitan

Jan 13, 2025
pulisher
Jan 12, 2025

Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated at Cantor Fitzgerald - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade - MSN

Jan 11, 2025
pulisher
Jan 07, 2025

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 07, 2025
pulisher
Jan 06, 2025

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of Stock - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Travere therapeutics chief medical officer sells shares totaling $47,714 By Investing.com - Investing.com Canada

Jan 06, 2025
pulisher
Jan 06, 2025

Travere therapeutics chief medical officer sells shares totaling $47,714 - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Travere Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

Travere Therapeutics (NASDAQ:TVTX) Trading Up 7.2%Here's Why - MarketBeat

Jan 02, 2025
pulisher
Jan 01, 2025

High Growth Tech Stocks in the United States to Watch - Simply Wall St

Jan 01, 2025
pulisher
Dec 30, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 30, 2024
pulisher
Dec 30, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Dec 30, 2024
pulisher
Dec 28, 2024

Geode Capital Management LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Dec 28, 2024
pulisher
Dec 28, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Geode Capital Management LLC - MarketBeat

Dec 28, 2024
pulisher
Dec 27, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $258,300.00 in Stock - MarketBeat

Dec 27, 2024
pulisher
Dec 27, 2024

Travere therapeutics CAO Calvin Sandra sells $258,277 in stock By Investing.com - Investing.com Canada

Dec 27, 2024
pulisher
Dec 26, 2024

Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance

Dec 26, 2024
pulisher
Dec 26, 2024

Barclays PLC Sells 17,544 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Dec 26, 2024
pulisher
Dec 21, 2024

State Street Corp Has $38.29 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - The Eastern Progress Online

Dec 20, 2024
pulisher
Dec 20, 2024

XTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha

Dec 19, 2024
pulisher
Dec 18, 2024

Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Canada

Dec 18, 2024
pulisher
Dec 17, 2024

(TVTX) Investment Analysis - Stock Traders Daily

Dec 17, 2024
pulisher
Dec 17, 2024

Y Intercept Hong Kong Ltd Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Dec 17, 2024
pulisher
Dec 15, 2024

Fmr LLC Acquires 31,772 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Dec 15, 2024
pulisher
Dec 15, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Dec 15, 2024
pulisher
Dec 14, 2024

The Manufacturers Life Insurance Company Purchases 17,931 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Dec 14, 2024
pulisher
Dec 12, 2024

Travere Therapeutics' SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Canada

Dec 12, 2024
pulisher
Dec 11, 2024

TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Dec 11, 2024
pulisher
Dec 10, 2024

Two Sigma Advisers LP Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Dec 10, 2024
pulisher
Dec 08, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd. - MarketBeat

Dec 08, 2024

Travere Therapeutics Inc (TVTX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):